Skip to main content
PEN $320.23 +0.35%
PEN logo
PEN · Penumbra Inc
Track PEN — free
$320.23 +1.12 (+0.35%) Q3 2025 earnings call transcript
Market Cap
$12.58B
Shares
39.41M
Volume · Nov 18 83.04K Avg daily vol (3M) 356.3K
All webcasts

Earnings call · FY2026 Q3

Penumbra Inc (PEN) Q3 2026 Earnings Call

Concluded Oct 29, 2026
Oct 29, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $410.14M +15.6% YoY
Diluted EPS $1.07 -8.5% YoY
Gross margin 68.3% +0.5 pp YoY
Net income $42.28M -7.8% YoY
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Oct 29, 2026
Penumbra Inc reported third-quarter 2026 revenue of $410.1 million, up 15.6%, global thrombectomy revenue of $279.2 million, up 18.1%, and net income of $42.3 million; pending acquisition by Boston Scientific Corporation led it to withhold full year 2026 guidance.
10-Q report · filed Oct 29, 2026
Penumbra agreed to be acquired by Boston Scientific Corporation for approximately $14.5 billion, with each share valued at $374 and closing expected in early 2027. Revenue for the nine months ended September 30, 2026 increased 15.4% to $1,174.9 million.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Thrombectomy$279.16M +18.1% YoY
Embolization and Access$130.99M +10.8% YoY
Full-screen source Call document